Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137034 | 1.00 | SLC7A5 (0.47) | SLC7A5ESR1POLBESR2CA2 | |
| SCHEMBL2296245 | 0.87 | CYP1A2 (0.47) | SLC7A5FOLH1 | |
| SCHEMBL2296250 | 0.87 | CYP1A2 (0.47) | SLC7A5FOLH1 | |
| SCHEMBL32681194 | 0.85 | OPRK1 (0.42) | SLC7A5ESR1ESR2CA2CAMK2A | |
| SCHEMBL14980577 | 0.84 | KDM6B (0.53) | SLC7A5ESR1POLBCA2OPRK1 | |
| SCHEMBL30736141 | 0.79 | SLC7A5 (0.51) | SLC7A5ESR1POLBESR2CA2 | |
| SCHEMBL14357545 | 0.79 | SLC7A5 (0.51) | SLC7A5ESR1POLBESR2CA2 | |
| SCHEMBL3209764 | 0.79 | SLC7A5 (0.42) | SLC7A5ESR1POLBESR2FOLH1 | |
| SCHEMBL1374628 | 0.78 | SLC7A5 (0.47) | SLC7A5ESR1POLBESR2CA2 | |
| SCHEMBL1374625 | 0.78 | SLC7A5 (0.47) | SLC7A5ESR1POLBESR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008085512-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-17 | — | — | WO | claimed |
| US-20080167493-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-07-10 | — | — | US | claimed |
| WO-2008085512-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167493-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167493-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | TH, HPD, PAH | SLC7A5 771/4885ESR1 2154/4885POLB 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.